Perrigo attributes flat second quarter sales to slow start to cough/cold season.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO SECOND QUARTER SALES FLAT AT $174.7 MIL. due to a slow start to the cough/cold season, the company said in a Feb. 7 release. "The second quarter was a difficult period for our company due to a very weak start to the cough and cold season this year, which negatively impacted sales of our largest product categories," Perrigo said. As a result, the firm explained, sales of cold remedies have been "below expectations.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.